DOTA-Lanreotide
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy[1].
Product Specifications
CAS Number
213187-44-1
UNSPSC
12352005
Target
Radionuclide-Drug Conjugates (RDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-lanreotide.html
Smiles
O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC4=C(C=CC=C4)C=C3)=O)=O)CC5=CC=C(C=C5)O)N[C@@H]1CC6=CNC7=CC=CC=C67
Molecular Formula
C70H95N15O17S2
Molecular Weight
1482.72
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041042-100 1x 100 µL
TRIM29 (TRIM29/1042), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
